H
Hans Martin
Researcher at Goethe University Frankfurt
Publications - 139
Citations - 16725
Hans Martin is an academic researcher from Goethe University Frankfurt. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 43, co-authored 134 publications receiving 16226 citations.
Papers
More filters
Journal ArticleDOI
Number and Migratory Activity of Circulating Endothelial Progenitor Cells Inversely Correlate With Risk Factors for Coronary Artery Disease
Mariuca Vasa,Stephan Fichtlscherer,Alexandra Aicher,Klaudia Adler,Carmen Urbich,Hans Martin,Andreas M. Zeiher,Stefanie Dimmeler +7 more
TL;DR: Patients with CAD revealed reduced levels and functional impairment of EPCs, which correlated with risk factors for CAD, and hypertension was identified as a major independent predictor for impaired EPC migration.
Journal ArticleDOI
Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI)
Birgit Assmus,Volker Schächinger,Claudius Teupe,Martina B. Britten,Ralf Lehmann,N. Döbert,Frank Grünwald,Alexandra Aicher,Carmen Urbich,Hans Martin,Dieter Hoelzer,Stefanie Dimmeler,Andreas M. Zeiher +12 more
TL;DR: In patients with AMI, intracoronary infusion of autologous progenitor cells appears to be feasible and safe and may beneficially affect postinfarction remodeling processes.
Journal ArticleDOI
HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway
Stefanie Dimmeler,Alexandra Aicher,Mariuca Vasa,Christiane Mildner-Rihm,Klaudia Adler,Michaela Tiemann,Hartmut Rütten,Stephan Fichtlscherer,Hans Martin,Andreas M. Zeiher +9 more
TL;DR: It is demonstrated that statins potently augment endothelial progenitor cell differentiation in mononuclear cells and CD34-positive hematopoietic stem cells isolated from peripheral blood.
Journal ArticleDOI
Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial.
Volker Schächinger,Birgit Assmus,Martina B. Britten,Jörg Honold,Ralf Lehmann,Claudius Teupe,Nasreddin Abolmaali,Thomas J. Vogl,Wolf-Karsten Hofmann,Hans Martin,Stefanie Dimmeler,Andreas M. Zeiher +11 more
TL;DR: Intracoronary infusion of progenitor cells (either BMC or CPC) is safe and feasible in patients after AMI successfully revascularized by stent implantation, suggesting functional regeneration of the infarcted ventricles.
Journal ArticleDOI
Transcoronary transplantation of progenitor cells after myocardial infarction.
Birgit Assmus,Jörg Honold,Volker Schächinger,Martina B. Britten,Ulrich Fischer-Rasokat,Ralf Lehmann,Claudius Teupe,Katrin Pistorius,Hans Martin,Nasreddin Abolmaali,Torsten Tonn,Stefanie Dimmeler,Andreas M. Zeiher +12 more
TL;DR: Intracoronary infusion of progenitor cells is safe and feasible in patients with healed myocardial infarction and is associated with moderate but significant improvement in the left ventricular ejection fraction after 3 months.